Martin Wisher und Development - Info zur Person

(1 - 9 von 14

)

Vaccine Bioprocess Development Course — ITQB

www.itqb.unl.pt

· Facilities of the Future (Alain Pralong, GSK); Quality Control of Vaccines (Martin Wisher, Bioreliance); Polysaccharide and Conjugate Vaccine ...

2019 Vaccines Process Development & Commercialization ...Massachusetts Institute of Technology

web.mit.edu

Martin Wisher, PhD view abstract | back to agenda. Senior Regulatory Consultant, Quality & Regulatory Management, MilliporeSigma.

2019 Vaccines Process Development & Commercialization Workshop

web.mit.edu

Martin Wisher, MilliporeSigma. Stefanie Frank, UCL. Case Study - Flu Vaccine Matthew Downham, AstraZeneca. June 13. Keynote Speaker Mark Feinberg, IAVI.

2017 Vaccines Process Development & Commercialization Workshop

web.mit.edu

Martin Wisher, PhD view abstract | back to agenda. Head of Regulatory Affairs, BioReliance. Dr. Wisher has more than 30 years of experience in biosafety ...

Animal Cell Technology: From Vaccines to Genetic Medicine - Google...

books.google.fr

DEVELOPMENT OF A HIGH SENSITIVITY RETROVIRUS SPECIFIC REVERSE TRANSCRIPTASE ASSAY Audrey Chang, Martin Wisher, Robert Bird, and Jeffrey M. Ostrove Microbiological Associates, Blackwell Road, Rockville MD and Stirling, Scotland Introduction: The safety testing of cell substrates used to ...

Verwandte Suchanfragen zu Martin Wisher

Audrey Chang
Gene Therapy
Mike Rubino

Robert Bird

Personen
Vorname "Martin" (86745)
Name "Wisher" (6)

sortiert nach Relevanz / Datum

Erweiterte Suche

Person-Suchen: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Martin Wisher und Development Person-Info

Vaccine Bioprocess Development Course — ITQB

2019 Vaccines Process Development & Commercialization ...Massachusetts Institute of Technology

2019 Vaccines Process Development & Commercialization Workshop

2017 Vaccines Process Development & Commercialization Workshop

Animal Cell Technology: From Vaccines to Genetic Medicine - Google...

Reducing the Risk During Cell and Gene Therapy ...Sigma-Aldrich

Development of a High Sensitivity Retrovirus Specific Reverse...

Ensuring Viral Safety of Viral Vaccines and VectorsBioprocess Development Forum